"Skin Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the SKIN.
| Descriptor ID |
D012878
|
| MeSH Number(s) |
C04.588.805 C17.800.882
|
| Concept/Terms |
Skin Neoplasms- Skin Neoplasms
- Neoplasms, Skin
- Neoplasm, Skin
- Skin Neoplasm
Cancer of Skin- Cancer of Skin
- Skin Cancers
- Cancer of the Skin
- Skin Cancer
- Cancer, Skin
- Cancers, Skin
|
Below are MeSH descriptors whose meaning is more general than "Skin Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Skin Neoplasms".
This graph shows the total number of publications written about "Skin Neoplasms" by people in this website by year, and whether "Skin Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 7 | 0 | 7 |
| 1996 | 7 | 1 | 8 |
| 1997 | 7 | 0 | 7 |
| 1998 | 7 | 0 | 7 |
| 1999 | 4 | 2 | 6 |
| 2000 | 13 | 2 | 15 |
| 2001 | 11 | 2 | 13 |
| 2002 | 16 | 1 | 17 |
| 2003 | 15 | 2 | 17 |
| 2004 | 13 | 1 | 14 |
| 2005 | 19 | 1 | 20 |
| 2006 | 24 | 3 | 27 |
| 2007 | 17 | 0 | 17 |
| 2008 | 30 | 0 | 30 |
| 2009 | 21 | 4 | 25 |
| 2010 | 20 | 5 | 25 |
| 2011 | 32 | 4 | 36 |
| 2012 | 28 | 4 | 32 |
| 2013 | 26 | 4 | 30 |
| 2014 | 26 | 6 | 32 |
| 2015 | 23 | 6 | 29 |
| 2016 | 24 | 3 | 27 |
| 2017 | 44 | 3 | 47 |
| 2018 | 32 | 1 | 33 |
| 2019 | 29 | 6 | 35 |
| 2020 | 41 | 5 | 46 |
| 2021 | 20 | 2 | 22 |
| 2022 | 32 | 1 | 33 |
| 2023 | 27 | 0 | 27 |
| 2024 | 33 | 1 | 34 |
| 2025 | 12 | 0 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Skin Neoplasms" by people in Profiles.
-
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025 Aug 01; 131(15):e70022.
-
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. J Clin Invest. 2025 Sep 16; 135(18).
-
Evaluating the consistency of SMARCB1 variant classification and assertions of genotype-phenotype relationships in ClinVar. Cancer Genet. 2025 Sep; 296-297:84-87.
-
Rare Adenoid Variant of Basal Cell Carcinoma in an African American Child With Nevoid Basal Cell Carcinoma Syndrome: Atypical Nodulocystic Presentation. Am J Dermatopathol. 2025 May 02; 47(7):531-535.
-
Screening and identification of versican as a sensitive biomarker and potential therapeutic target in basal cell carcinoma. Int J Med Sci. 2025; 22(10):2488-2501.
-
Update on Cancer and Central Nervous System Tumor Surveillance in Pediatric NF2-, SMARCB1-, and LZTR1-Related Schwannomatosis. Clin Cancer Res. 2025 Apr 14; 31(8):1400-1406.
-
Transcriptomic signatures in peripheral CD4+T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation. Front Immunol. 2025; 16:1529707.
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
-
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76?K trial. Eur J Cancer. 2025 May 02; 220:115371.
-
Anticipation, perception, and recollection of acute pain from local anesthesia injection prior to Mohs surgery. Arch Dermatol Res. 2025 Feb 25; 317(1):490.